137 related articles for article (PubMed ID: 1419336)
1. [A history and prospect of adoptive immunotherapy against malignant glioma--past, now and future].
Nitta T
No To Shinkei; 1992 Jul; 44(7):605-13. PubMed ID: 1419336
[No Abstract] [Full Text] [Related]
2. [Cellular immunotherapy for malignant glioma].
Okamoto Y; Yamashita J
Nihon Rinsho; 2005 Sep; 63 Suppl 9():557-62. PubMed ID: 16201581
[No Abstract] [Full Text] [Related]
3. Lymphokine-activated killer lymphocytes: LAK and interleukin-2 in the treatment of malignancies of the central nervous system.
Blacklock JB; Grimm EA
Immunol Ser; 1989; 48():93-9. PubMed ID: 2488328
[No Abstract] [Full Text] [Related]
4. Adjuvant adoptive immunotherapy for pediatric recurrent brain tumors.
Lillehei KO; Johnson SD; McCleary EL; Mitchell DH; Schiltz PM; Kruse CA
Online J Curr Clin Trials; 1993 Dec; Doc No 111():[806 words; 5 paragraphs]. PubMed ID: 8305997
[No Abstract] [Full Text] [Related]
5. Immunotherapy with stimulated autologous lymphocytes in a case of a juvenile anaplastic glioma.
Thomas C; Schober R; Lenard HG; Lumenta CB; Jacques DB; Wechsler W
Neuropediatrics; 1992 Jun; 23(3):123-5. PubMed ID: 1641079
[TBL] [Abstract][Full Text] [Related]
6. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2.
Tzeng JJ; Barth RF; Clendenon NR; Gordon WA
Cancer Res; 1990 Jul; 50(14):4338-43. PubMed ID: 2364388
[TBL] [Abstract][Full Text] [Related]
7. [Our experience with lymphocytes activated against cancer: CTL cells].
Marcellino LR; Vinciguerra M; Marcellino MV; Sessa E
G Chir; 1997 Oct; 18(10):605-7. PubMed ID: 9479972
[TBL] [Abstract][Full Text] [Related]
8. The cellular immunotherapy of primary brain tumors.
Hayes RL
Rev Neurol (Paris); 1992; 148(6-7):454-66. PubMed ID: 1448666
[TBL] [Abstract][Full Text] [Related]
9. Rat mitogen-stimulated lymphokine-activated T killer cells: production and effects on C6 glioma cells in vitro and in vivo in the brain of Wistar rats.
Carson WE; Jakowatz JG; Yamamoto R; Fitzgerald T; Gupta S; Vayuvegula B; Lucci JA; Beckman MT; Dulkanchainun S; Granger GA
J Immunother (1991); 1991 Apr; 10(2):131-40. PubMed ID: 2043593
[TBL] [Abstract][Full Text] [Related]
10. Adoptive immunotherapy of experimental tumors using cytotoxic lymphocytes to carry and deliver toxins.
Zanovello P; Rosato A; Bronte V; Cerundolo V; Collavo D
Ann Ist Super Sanita; 1991; 27(1):91-5. PubMed ID: 1958033
[TBL] [Abstract][Full Text] [Related]
11. [Adoptive immunotherapy in patients with multiple hepatic cancers using lymphokine activated killer cells (LAK) and interleukin-2].
Kanai T; Monden M; Takeda T; Gotoh M; Sakon M; Umeshita K; Hasuike Y; Sakita I; Nakano H; Yoshida T
Gan To Kagaku Ryoho; 1993 Aug; 20(11):1457-60. PubMed ID: 8396896
[TBL] [Abstract][Full Text] [Related]
12. Adoptive immunotherapy with recombinant interleukin 2, LAK and TIL.
Kurnick JT; Kradin RL
Allergol Immunopathol (Madr); 1991; 19(5):209-14. PubMed ID: 1811418
[No Abstract] [Full Text] [Related]
13. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
14. [Autologous tumor specific immunotherapy of refractory cancers with ex vivo-generated T cells stimulated by autologous tumor cell].
Toh U; Yamana H; Kido K; Mine T; Fujii T; Horiuchi H; Sasatomi T; Ishibashi N; Yutani S; Fujita H; Shirouzu K
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1566-70. PubMed ID: 14619465
[TBL] [Abstract][Full Text] [Related]
15. [Observations on the local administration of autologous lymphokine activated killer cells and recombinant interleukin-2 in patients with malignant gliomas].
Yoshida S; Takai N; Ono K; Saito T; Tanaka R
No To Shinkei; 1988 Feb; 40(2):119-25. PubMed ID: 3259433
[TBL] [Abstract][Full Text] [Related]
16. [Augmentation of therapeutic effect of adoptive immunotherapy through a synergy between transferred killer cells and host's fresh lymphocytes].
Kan N; Yamasaki S; Harada T; Satoh K; Ichinose Y; Moriguchi Y; Kodama H; Ohgaki K
Hum Cell; 1992 Sep; 5(3):236-42. PubMed ID: 1467322
[TBL] [Abstract][Full Text] [Related]
17. Adoptive cell transfer therapy for malignant gliomas.
Ishikawa E; Takano S; Ohno T; Tsuboi K
Adv Exp Med Biol; 2012; 746():109-20. PubMed ID: 22639163
[TBL] [Abstract][Full Text] [Related]
18. Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take.
Kruse CA; Lillehei KO; Mitchell DH; Kleinschmidt-DeMasters B; Bellgrau D
Proc Natl Acad Sci U S A; 1990 Dec; 87(24):9577-81. PubMed ID: 2263613
[TBL] [Abstract][Full Text] [Related]
19. Adoptive immunotherapy with adherent lymphokine-activated killer (A-LAK) cells in glioblastoma multiforme.
Munari L; Silvani A; Passerini CG; Radrizzani M; Parmiani G; Boiardi A
J Neurosurg Sci; 1990; 34(3-4):283-8. PubMed ID: 1965907
[TBL] [Abstract][Full Text] [Related]
20. Clinical use of interleukin-2 in treating cancer.
Patterson DL; Wiemann MC
Indiana Med; 1991 Aug; 84(8):534-7. PubMed ID: 1918915
[No Abstract] [Full Text] [Related]
[Next] [New Search]
